Today, on HIV Vaccine Awareness Day 2022, WHV would like to thank their partners for their crucial role in the vaccine development program of WHV’s second generation HIV vaccine candidate PDPHV. A team comprised of renowned HIV vaccine research groups, competent CROs, and talented individual specialists has been providing WHV with high quality products and expertise, assuring a smooth operation for the new biotech company over the past four years. WHV is grateful for their continued partnership and support, which has been essential in successfully moving PDPHV through the subsequent clinical testing phases.
More importantly, WHV wants to extent their gratitude towards the many volunteers who participated and continue to participate in the HIV vaccine trials, including HVTN124 and WHV138. Without all of the healthy individuals who volunteer as a research subject, the search for a safe and effective preventative HIV vaccine would not be possible. As the phase 1b WHV138 trial is almost fully enrolled, the investigation of the safety and immunogenicity of this polyvalent DNA/Protein HIV vaccine candidate is progressing well. Once the trial is completed and data can be analyzed, newly acquired knowledge from this study will help the entire HIV vaccine field advance towards finding a safe and effective HIV vaccine.
